跳至主要内容
临床试验/ACTRN12609000975291
ACTRN12609000975291已完成2 期

In post stroke patients, treatment with nefiracetam decreases the severity of apathy

Fremantle Hospital and Health Service0 个研究点目标入组 122 人开始时间: 2009年11月11日最近更新:

试验速览

阶段
2 期
状态
已完成
入组人数
122

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
40 Years 至 90 Years(—)
性别
All

入选标准

  • 1. Clinical and neurological findings consistent with either hemispheric, brainstem or cerebellar stroke 2. apathy present after stroke 3. able to undergo assessment and take oral medication 4.be cared for by a reliable spouse who can be responsible for administering dose

排除标准

  • 1. patients with major depression post stroke 2. stroke resulting from aneurysm, ateriovenous malformation, head injury, intracranial tumour or neoplastic process 3. prestroke dementia 4. severe language comprehension deficits 5. comorbid alcohol or drug abuse 6. severe medical comorbidity 7. current use of neuroleptic or drugs repported to affect apathy 8. apathy resulting from any condition other than stroke 9. Severe renal disease: BUN >=17.85mmol/L; Creatinine >= 176.89 umol/L; proteinuria (dipstick >= +2

研究者

相似试验

A randomised double blind, placebo-controlled study... | 临床试验